Close Menu

NEW YORK (GenomeWeb) — Co-Diagnostics announced today that it has sold $3 million worth of preferred stock in a transaction that eliminates the Salt Lake City, Utah-based company's debt.

According to Co-Diagnostics, the preferred shares are convertible into common stock at a price of $1.20 per share. The deal included negotiating the conversion of a $2 million note to preferred stock, as well as the sale of an additional $1 million of preferred stock for cash.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.